Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
项目 1:按种族/民族发现基于肿瘤组织的新型致死性结直肠癌预测因子
基本信息
- 批准号:10044049
- 负责人:
- 金额:$ 33.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAfrican AmericanAgeAlaska NativeAnti-Inflammatory AgentsAspirinBody mass indexCancer ControlCancer EtiologyCessation of lifeClinicalColorectal CancerConsensusDataDevelopmentDiagnosisEnsureEthnic OriginEthnic groupEtiologyExpression ProfilingFamily history ofFormalinFrequenciesGene ExpressionGoalsHispanicsImmuneImmune responseIncidenceIndividualInterventionMalignant NeoplasmsMethodsMolecularMolecular ProfilingMutationNative AmericansNative-BornNested Case-Control StudyNot Hispanic or LatinoOutcomePIK3CA geneParaffin EmbeddingPatientsPopulationPrevention strategyPrimary PreventionPrognostic MarkerRNARaceResourcesRiskRisk FactorsSample SizeSamplingSecondary PreventionSelection for TreatmentsSmoking HistorySpecimenStromal CellsSurvival RateTimeTumor TissueUnderserved PopulationUnited StatesWorkbasecancer diagnosiscancer health disparitycancer preventionclinical decision-makingclinically actionablecolon cancer patientscolorectal cancer riskdesigndisparity reductionexperiencefeedinggenetic signatureimprovedimproved outcomemalignant breast neoplasmmedically underserved populationmolecular subtypesmortalitymultidimensional datanew therapeutic targetnovelnovel therapeuticsracial and ethnicracial and ethnic disparitiesracial differencesexsuccesstherapeutic targettranscriptome sequencingtranslational research programtumortumor microenvironment
项目摘要
Project summary/abstract
While improvements in colorectal cancer (CRC) outcomes have been made over the past several decades,
pronounced disparities in CRC incidence and mortality rates by race/ethnicity persist in the United States. In
particular, CRC incidence and mortality rates among Alaska Native people (a particularly understudied
population) are 124% and 148% higher, respectively, compared to the overall national rates, and among
African Americans they are 21% and 39% higher, respectively. Our primary overarching goal is to reduce
disparities in CRC mortality, particularly those experienced by Alaska Natives and African Americans, through
improving approaches to identify patients with aggressive CRC at diagnosis and discovering novel potential
therapeutic targets relevant to these populations. To address this goal, we will conduct a nested case-control
study that utilizes highly clinically annotated tumor tissue specimens that are readily available from several
resources. Cases are CRC patients who died of CRC within 5 years of their diagnosis, and controls are
matched CRC patients who survived at least as long as the duration between diagnosis and death of the case
that they are matched to. We will include four groups of patients defined by race/ethnicity: Alaska Native
people, African Americans, Hispanics, and non-Hispanic whites with 70 cases of lethal CRC and 140 CRC
controls from each group (total n=840). To discover novel prognostic markers, we will perform RNAseq
analyses on RNA extracted from formalin-fixed paraffin embedded tumor material. The specific aims of this
proposal are as follows: 1. Assess differences in gene expression profiles across four racial/ethnic groups and
their relationships to selected CRC risk factors; 2. Discover predictors of CRC mortality across and within four
different racial/ethnic groups; and 3. Characterize and evaluate differences in the immune and stromal cell
populations in the tumor microenvironment associated with CRC mortality, overall and by race/ethnicity. This
study will generate novel multi-ethnic high-dimensional data that we envision feeding into larger studies with
translational goals focused on advancing novel intervention targets for primary and secondary prevention, and
developing clinically useful predictors of poor CRC outcomes that can be used to guide clinical decision
making. This study is designed to generate findings that will be of particular benefit to underserved populations
as this work is aimed directly at reducing long-standing racial/ethnic disparities in CRC outcomes.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher I Li其他文献
Christopher I Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher I Li', 18)}}的其他基金
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
项目 1:按种族/民族发现基于肿瘤组织的新型致死性结直肠癌预测因子
- 批准号:
10466937 - 财政年份:2020
- 资助金额:
$ 33.81万 - 项目类别:
Translational Research Program in Colorectal Cancer Disparities
结直肠癌差异的转化研究计划
- 批准号:
10601404 - 财政年份:2020
- 资助金额:
$ 33.81万 - 项目类别:
Translational Research Program in Colorectal Cancer Disparities
结直肠癌差异的转化研究计划
- 批准号:
10244961 - 财政年份:2020
- 资助金额:
$ 33.81万 - 项目类别:
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
项目 1:按种族/民族发现基于肿瘤组织的新型致死性结直肠癌预测因子
- 批准号:
10601406 - 财政年份:2020
- 资助金额:
$ 33.81万 - 项目类别:
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
项目 1:按种族/民族发现基于肿瘤组织的新型致死性结直肠癌预测因子
- 批准号:
10244963 - 财政年份:2020
- 资助金额:
$ 33.81万 - 项目类别:
Translational Research Program in Colorectal Cancer Disparities
结直肠癌差异的转化研究计划
- 批准号:
10044047 - 财政年份:2020
- 资助金额:
$ 33.81万 - 项目类别:
Translational Research Program in Colorectal Cancer Disparities
结直肠癌差异的转化研究计划
- 批准号:
10466935 - 财政年份:2020
- 资助金额:
$ 33.81万 - 项目类别:
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
优化癌症筛查人群研究协调中心 (PROSPR) (U24)
- 批准号:
10642674 - 财政年份:2018
- 资助金额:
$ 33.81万 - 项目类别:
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
优化癌症筛查人群研究协调中心 (PROSPR) (U24)
- 批准号:
10380156 - 财政年份:2018
- 资助金额:
$ 33.81万 - 项目类别:
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
优化癌症筛查人群研究协调中心 (PROSPR) (U24)
- 批准号:
9898340 - 财政年份:2018
- 资助金额:
$ 33.81万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 33.81万 - 项目类别: